Good morning :)
Switch to
Place Order

Lasa Supergenerics Ltd

LASA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹257 cr, stock is ranked 1,467
High RiskStock is 3.61x as volatile as Nifty
63.401.55 (-2.39%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹257 cr, stock is ranked 1,467
High RiskStock is 3.61x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
11.32
PB RatioPB Ratio
1.82
Dividend YieldDiv. Yield
0.39%
Sector PESector PE
38.41
Sector PBSector PB
5.12
Sector Div YldSctr Div Yld
0.68%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lasa Supergenerics Limited is engaged in the manufacturing of anthelmintics/veterinary active pharmaceutical ingredient (API). The Company also manufactures bulk drugs

Investor PresentationView older 

Oct 28, 2020

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2018201920202021246.94170.04167.49202.4412.33-12.043.6222.78
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Reply to Clarification Sought 
Announced OnOct 21, 2021

LASA: The Exchange had sought clarification from Lasa Supergenerics Limited with respect to announcement dated 18-Oct-2021, regardingᅡᅠ Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify following: 1. Expected quantum of loss/damage caused; The response of the Company is attached. | Download

LASA: The Exchange had sought clarification from Lasa Supergenerics Limited with respect to announcement dated 18-Oct-2021, regardingᅡᅠ Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify following: 1. Expected quantum of loss/damage caused; The response of the Company is attached. | Download

Clarification 
Announced OnOct 19, 2021
LASA: The Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 18-Oct-2021, regardingᅡᅠ Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify following: 1. Expected quantum of loss/damage caused;The response of the Company is awaited.
LASA: The Exchange has sought clarification from Lasa Supergenerics Limited with respect to announcement dated 18-Oct-2021, regardingᅡᅠ Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify following: 1. Expected quantum of loss/damage caused;The response of the Company is awaited.
Cash Dividend 
Ex. DateSep 15, 2021

Final • Div/Share: ₹ 0.25

See all events